Gilotrif (Afatinib)

Brand Name

Gilotrif

Generic Name

Afatinib

View Brand Information

FDA approval date: July 12, 2013

Classification: Kinase Inhibitor

Form: Tablet

What is Gilotrif (Afatinib)?

GILOTRIF is a kinase inhibitor indicated for: First-line treatment of patients with metastatic non-small cell lung cancer whose tumors have non-resistant epidermal growth factor receptor mutations as detected by an FDA-approved test.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC mutations, and who have not received any prior therapy for advanced disease. Participants will be ra...

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Who is this study for: Patients with Lymphoma, Myeloma, Tumors

Enrollment Status: Recruiting

Publish Date: April 02, 2026

Intervention Type: Drug

Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)

Study Phase: Phase 2

Summary: The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a pati...

Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Who is this study for: Patients with advanced cutaneous squamous cell carcinoma

Enrollment Status: Recruiting

Publish Date: April 01, 2026

Intervention Type: Drug

Study Drug: Afatinib

Study Phase: Phase 2

Summary: The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.

View All Clinical Trials